Chardan analyst Keay Nakae lowered the firm’s price target on Femasys to $10 from $12 and keeps a Buy rating on the shares after the company reported Q2 results. The firm said its lower price target reflects a higher projected future share count as modeled future capital raises are expected to be more dilutive due to the decline in share price over the last quarter.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FEMY:
- Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update
- Femasys sees cash runway into July 2025
- Femasys reports Q2 EPS (21c), consensus (17c)
- Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam
- Femasys receives CE Mark approval for four women’s health products